Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC

被引：25
|
作者：
Zhang, Chao [1 ,2 ]
Yan, Li-Xu [2 ,3 ]
Jiang, Ben-Yuan [1 ,2 ]
Wu, Yi-Long [1 ,2 ]
Zhong, Wen-Zhao [1 ,2 ]
机构：
[1] Guangdong Prov Peoples Hosp, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou 510080, Guangdong, Peoples R China
[3] Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 06期
关键词：
D O I：
10.1016/j.jtho.2019.12.133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E95 / E99
页数：5
相关论文
共 50 条
  • [1] Alectinib: A Review in Advanced, ALK-Positive NSCLC
    Julia Paik
    Sohita Dhillon
    Drugs, 2018, 78 : 1247 - 1257
  • [2] Alectinib: A Review in Advanced, ALK-Positive NSCLC
    Paik, Julia
    Dhillon, Sohita
    DRUGS, 2018, 78 (12) : 1247 - 1257
  • [3] Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib
    Zhang, Chao
    Wu, Yi-Long
    Zhong, Wen-Zhao
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E234 - E236
  • [4] Alectinib shows CNS efficacy in ALK-positive NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (10): : E520 - E520
  • [5] Alectinib surpasses crizotinib for untreated ALK-positive NSCLC
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2017, 18 (07): : E377 - E377
  • [6] Alectinib in crizotinib-resistant, ALK-positive NSCLC
    Jassem, Jacek
    LANCET ONCOLOGY, 2016, 17 (02): : 134 - 135
  • [7] The Optimal ALK inhibitor in Advanced ALK-Positive NSCLC Patients: An Indirect Comparison Between Brigatinib and Alectinib
    Chen, G.
    Zhang, Y.
    Zhou, H.
    Zhao, S.
    Liu, J.
    Hong, S.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1056 - S1056
  • [8] Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
    Lin, Jessica J.
    Zhu, Viola W.
    Schoenfeld, Adam J.
    Yeap, Beow Y.
    Saxena, Ashish
    Ferris, Lorin A.
    Dagogo-Jack, Ibiayi
    Farago, Anna F.
    Taber, Angela
    Traynor, Anne
    Menon, Smitha
    Gainor, Justin F.
    Lennerz, Jochen K.
    Plodkowski, Andrew J.
    Digumarthy, Subba R.
    Ignatius, Sai-Hong
    Shaw, Alice T.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1530 - 1538
  • [9] ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
    Noe, Johannes
    Lovejoy, Alex
    Ou, Sai-Hong Ignatius
    Yaung, Stephanie J.
    Bordogna, Walter
    Klass, Daniel M.
    Cummings, Craig A.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 601 - 608
  • [10] Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
    Hiroshi Hashimoto
    Kazuyuki Komori
    Koji Kameda
    Shinichi Taguchi
    Yuichi Ozeki
    Surgical Case Reports, 8
12345